Patent №
US 9,307,942
Granted
2016-04-12
Filed 2015
Owner
GILROSE PHARMACEUTICALS, LLC
Lab
—
AI components
2
nlp · speech
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
14793829
A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
AI classification
Speech0.98
Natural language0.54
Machine learning0.00
Evolutionary computation0.00
Knowledge representation0.00
AI hardware0.00
Vision0.00
Planning0.00
Ownership
GILROSE PHARMACEUTICALS, LLC
assignment · 360460334
Assignors
ROSEMAN, BRUCE, KAPLAN, GILLA
On an employer assignment, the assignors are typically the inventors.
From the same owner
PRE-FRONTAL CORTEX PROCESSING DISORDER SPEECH, GAIT AND LIMB IMPAIRMENTS TREATMENTUS 11,102,953 · 2021PRE-FRONTAL CORTEX PROCESSING DISORDER GAIT AND LIMB IMPAIRMENTS TREATMENTUS 9,682,073 · 2017PHARMACEUTICAL INTERVENTION AND METHOD FOR TREATING AN APRAXIA OF SPEECH IN CHILDRENUS 9,220,712 · 2015TREATMENT OF CEREBRAL PALSY IMPAIRED SPEECH IN CHILDRENUS 9,161,718 · 2015METHOD OF TREATING APRAXIA OF SPEECH IN CHILDRENUS 9,089,563 · 2015